Abstract: Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in solid tumors. To better understand the mechanism of action of these drugs, we examined the effects of AZA and DAC in a panel of non-small cell lung cancer (NSCLC) cell lines. Of 5 NSCLC lines tested in a cell viability assay, all were sensitive to AZA (EC 50 of 1.8-10.5 µM), while only H1299 cells were equally sensitive to DAC (EC 50 of 5.1 µM). In the relatively DAC-insensitive cell line A549, both AZA and DAC caused DNA methyltransferase I depletion and DNA hypomethylation; however, only AZA significantly induced markers of DNA damage and apoptosis, suggesting that mechanisms in addition to, or other than, DNA hypomethylation are important for AZA-induced cell death. Cell cycle analysis indicated that AZA induced an accumulation of cells in sub-G1 phase, whereas DAC mainly caused an increase of cells in G2/M. Gene expression analysis of AZA-and DAC-treated cells revealed strikingly different profiles, with many genes distinctly regulated by each drug. In summary, while both AZA and DAC caused DNA hypomethylation, distinct effects were demonstrated on regulation of gene expression, cell cycle, DNA damage, and apoptosis.
Introduction
Azacitidine (AZA) (5-azacytidine, Vidaza ® ; Celgene Corporation, Summit, NJ) and decitabine (DAC) (2'-deoxy-5-azacytidine, Dacogen ® ; Eisai Inc., Woodcliff Lake, NJ) are used clinically for the treatment of myelodysplastic syndromes (MDS), a heterogeneous group of bone marrow stem cell disorders.
1,2 Both AZA and DAC are cytidine nucleoside analogs that become incorporated into newly synthesized DNA, where they bind DNA methyltransferases (DNMTs) in an irreversible, covalent manner. 3, 4 The sequestration of DNMTs prevents maintenance of the methylation state of DNA, leading to DNA hypomethylation. 5, 6 As a consequence, genes previously silenced by DNA hypermethylation can be re-expressed upon treating cancer cell lines with these DNMT inhibitors. 7, 8 Re-expression of aberrantly methylated genes involved in normal cell cycle control, differentiation, and apoptotic pathways is believed to contribute to the anticancer effects of these drugs. 9 Clinical activities of AZA and DAC are best established in the hematological malignancies MDS and acute myeloid leukemia (AML), cancers with a high frequency of aberrantly methylated genes. 10 Aberrant DNA methylation of genes involved in DNA repair, cell adhesion, cell cycle, and cell death has also been reported in multiple types of solid cancers, including colon, stomach, breast, ovary, kidney, and lung. 
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For example, in non-small cell lung cancer (NSCLC), hypermethylation of tumor suppressor genes RAS association domain family 1A (RASSF1A), adenomatous polyposis coli (APC), fragile histidine triad (FHIT), and p16 INK4A has been associated with poor survival. [12] [13] [14] [15] Clinical trials investigating the use of AZA and DAC in solid tumors have been reported, although response rates were poor. In a Phase I study of DAC in patients with cancers involving the lungs, esophagus, and pleura, no objective responses were observed. 16 Similar outcomes were obtained with DAC in patients with other forms of solid tumors. 17 In a Phase II trial of AZA in patients with solid tumors, the responses were minimal and transient. 18 The clinical response rate was also low for the combination of AZA and phenylbutyrate in patients with refractory solid tumors. 19 A better understanding of the mechanistic activities of AZA and DAC will provide insights into rational use of these agents as therapies for solid tumor patients, including potential uses as combination therapies, adjuvant therapies, and maintenance therapies. Here, we directly compared the in vitro effects of AZA and DAC on cell viability, DNMT1 protein levels, DNA methylation, DNA damage, apoptosis, cell cycle, and gene expression in NSCLC cell lines. Although AZA and DAC caused similar effects on DNA-mediated markers such as DNMT1 depletion and DNA methylation, the drugs showed very different effects on cell viability, DNA damage, apoptosis, cell cycle, and gene expression.
Results

AZA and DAC have differential effects on NsCLC cell viability
AZA and DAC were compared in a panel of 5 NSCLC cell lines (A549, H1975, H460, H23, and H1299) for their effects on cell viability ( Figure 1 and Supporting Information Figure 1 ). AZA reduced cell viability by at least 75% at high concentrations, with EC 50 values of 1.8-10.5 µM (Table 1) . In contrast, DAC did not reduce cell viability more than 55%, and EC 50 values were not reached in 4 (A549, H1975, H460, and H23) of the 5 NSCLC cell lines tested. In H1299 
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AZA and DAC mechanisms of action in NsCLC cells, DAC EC 50 values were calculated; however, the 95% confidence intervals for the EC 50 values were poor (data not shown). The EC 50 values for AZA and DAC are similar to those reported for drugs commonly used in NSCLC, including gemcitabine, cisplatin, and carboplatin. [20] [21] [22] The distinct dose-response curves and EC 50 values indicate differential sensitivities of these NSCLC cell lines to AZA and DAC.
AZA and DAC cause DNMT1 depletion and DNA hypomethylation
To determine whether the differential sensitivities of NSCLC cell lines to AZA versus DAC in cell viability assays reflected differences in the incorporation of each drug into DNA, DNMT1 protein depletion and DNA hypomethylation were evaluated as indirect measures of drug incorporation into DNA. When A549 and H1299 cells were treated with AZA or DAC for 20 hours, DNMT1 protein levels were reduced ( Figure 2 ). Dose-dependent decreases in DNMT1 protein were observed with AZA, while near-maximal reduction of DNMT1 protein was observed at the lowest concentration (0.05 µM) of DAC. In A549 cells, DNMT1 depletion caused by 5 µM AZA was not as much as that caused by 0.5 or 1 µM AZA, possibly as a consequence of cell growth inhibition at the higher AZA concentration. 23 Reduced DNMT1 levels were detected as early as 4 hours after drug treatment (Supporting Information Figure 2 ). Similar results were obtained in the H460 and H23 cell lines (data not shown).
We next determined whether AZA and DAC caused DNA hypomethylation by examining the methylat ion status of LINE-1 elements in A549 and H1299 cells treated for 48 hours (Figure 3 ) or 72 hours (Supporting Information Figure 3 ). Both AZA and DAC decreased LINE-1 methylation; however, DAC was 3-to 10-fold more potent. Peak hypomethylation was observed at 0.3-1.0 µM AZA and 0.1 µM DAC. LINE-1 methylation was unaffected at the highest DAC concentration tested, possibly as a consequence of cell growth inhibition. 23 DAC modulated the DNA-mediated markers (DNMT1 depletion and DNA hypomethylation) in both cell lines, suggesting that the relative insensitivity to DAC in cell viability assays cannot be attributed to a lack of drug uptake, phosphorylation, and DNA incorporation. These findings rule out dysfunctional deoxycytidine kinase, the rate-limiting kinase in the phosphorylation of DAC, as a possible mechanism of relative DAC-insensitivity, 24 and suggest that mechanisms in addition to DNA incorporation are responsible for the greater sensitivity of NSCLC cell viability to AZA.
AZA, but not DAC, robustly induces markers of DNA damage and apoptosis Phase contrast images of A549 cell cultures after 3 days of drug treatment showed reduced cell numbers and increased debris in AZA-treated cell cultures, but healthy-looking cells in DAC-treated cultures ( Figure 4 ). These findings confirmed results of the cell viability assays (Figure 1 ). To examine the mechanism(s) of drug-induced cell death, A549 and H1299 NSCLC cell lines were treated with AZA or DAC for 24 or 48 hours, and markers of double-strand DNA (dsDNA) damage (histone-H2AX(ser139) phosphorylation) and apoptosis (PARP cleavage) were evaluated by Western blot ( Figure 5 and data not shown). AZA dose-dependently induced histone-H2AX(ser139) phosphorylation and PARP cleavage in A549 cells. Similar results were observed in the H460 cell line (data not shown). There was relatively high basal phosphorylation of histone-H2AX(ser139) in H1299 cells, which was further increased by 10 µM AZA.
High concentrations of AZA also induced PARP cleavage in H1299 cells. In A549 and H1299 cells, DNMT1 protein was completely depleted by DAC treatment; however, neither histone-H2AX(ser139) phosphorylation nor PARP cleavage were induced.
As AZA induced PARP cleavage, we further examined early-apoptotic (AnnexinV-FITC + and 7-AAD − ) and lateapoptotic (AnnexinV-FITC + and 7-AAD + ) cell populations by flow cytometry in A549 and H1299 cells treated with AZA (3 µM) or DAC (3 µM) for 72 hours ( Figure 6 ). AZA (3 µM) treatment of A549 and H1299 cells caused a significant increase in the early-and late-apoptotic populations ( Figures 6B and 6C ). DAC did not significantly cause an increase in these populations. These results demonstrated that AZA, but not DAC, induced dsDNA damage and apoptosis in NSCLC cell lines.
DAC-treated h1299 cells show delayed DNA damage response
AZA and DAC appear to be incorporated into DNA of NSCLC cell lines, as both drugs induced DNMT1 depletion ( Figure 2 ) and DNA hypomethylation ( Figure 3 ). It was therefore surprising that 48-hour treatment with DAC did not induce dsDNA damage (histone-H2AX(ser139) phosphorylation) in A549 and H1299 cells ( Figure 5 ). To better define the DNA damage response of NSCLC cell lines treated with AZA and DAC, we treated NSCLC cell lines with the drugs for an extended period of time. A549 and H1299 cells were treated with AZA or DAC for 6 days and lysates were collected on days 3 and 6 ( Figure 7 ). At the 3-day time point in both cell lines, the results were 
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AZA and DAC mechanisms of action in NsCLC for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PArP, phospho-histone-h2AX(ser139), and total histone-h2AX. alphatubulin was used as a loading control. Abbreviations: AZA, azacitidine; DAC, decitabine; DNMT1, DNA methyltransferase 1; NsCLC, non-small cell lung cancer.
similar to those at the 24-and 48-hour time points; AZA, but not DAC, induced histone-H2AX(ser139) phosphorylation and PARP cleavage. In A549 cells, even after 6 days of daily treatment with DAC, there was no induction of histone-H2AX(ser139) phosphorylation and PARP cleavage ( Figure 7 ). The EC 50 values for AZA and DAC were 4.4 µM and 2.5 µM, respectively, for A549 cells after 6 days of treatment (Supporting Information Table 1 ). Although the calculated EC 50 value for DAC was lower than that of AZA, DAC did not reduce cell viability more than 75%, while AZA almost completely inhibited cell viability (Supporting Information Figure 4) . In H1299 cells, substantial histone-H2AX(ser139) phosphorylation, without much effect on PARP cleavage, was observed after 6 days of DAC treatment (Figure 7 ). Consistent with these results, phase contrast images of H1299 cells treated with DAC for a prolonged period did not show many cells under going apoptosis. Rather, prolonged treatment of H1299 cells resulted in fewer cells that are enlarged (data not shown). These results suggest that DAC may have a delayed effect on inducing DNA damage in NSCLC cell lines.
AZA and DAC differentially affect the cell cycle
The effects of AZA and DAC on cell cycle distribution were evaluated in A549 and H1299 cells treated for 72 hours (Figure 8 ). AZA dose-dependently increased the sub-G1 population in A549 cells, consistent with the induction of apoptosis (Figures 4-6) . AZA also caused a minor increase in the sub-G1 population in H1299 cells (Figure 8) , consistent with the induction of early-, rather than late-, apoptotic cell population at this time point ( Figure 6 ). DAC also caused a minor increase in the sub-G1 population in these cell lines; however, the more prominent effect of DAC was an increase in the G2/M population.
AZA and DAC modulate expression of different sets of genes
Although both AZA and DAC caused DNMT1 depletion and DNA hypomethylation in NSCLC cell lines, the drugs had very different effects on cell viability, DNA damage, apoptosis, and cell cycle. To better understand the molecular pathways regulated by each drug, A549 and H1299 cells were treated with a dose range (0.3-3.0 µM) of AZA or DAC for 48 hours, and effects on gene expression were assessed by microarray analysis. The total number of genes regulated by AZA or DAC, and the overlap of regulated genes, are presented in Table 2 . At the lower drug concentration (0.3 µM), AZA and DAC modulated few genes, with DAC modulating 4-to 20-fold more genes than AZA. At the higher drug concentrations (1 and 3 µM), many more genes were modulated, with AZA typically modulating 2-to 5-fold more genes than DAC. Interestingly, the number of genes modulated in common between the 2 drugs was low (6%-22%). For example, in A549 cells, AZA (3 µM) and DAC (3 µM) commonly upregulated 66 genes, while AZA uniquely upregulated 636 genes and DAC uniquely upregulated 413 genes ( Table 2) .
Functional groupings of the modulated genes were determined using Gene Ontology classifications in NextBio. Different biogroups were regulated by each drug. The top 200 biogroups most significantly regulated by each drug (at 3 µM) are shown in Supporting Information Tables 2-5 . In H1299 cells, AZA treatment caused a general downregulation of genes within the "cell cycle", "metabolic process", and "biosynthetic process" biogroups. DAC treatment of H1299 cells caused a general upregulation of genes within the "cell differentiation" biogroup. In A549 cells, AZA treatment 
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Nguyen et al caused downregulation of genes involved in extracellular matrix, while DAC treatment caused downregulation of genes involved in cell cycle. Aside from the regulation of genes related to extracellular matrix, these results are similar to the gene expression data from AML cell lines treated with AZA and DAC. 25 Interestingly, AZA treatment of A549 and H1299 cells caused a general upregulation of genes within the "response to DNA damage stimulus" and "DNA repair" biogroups ( Figure 9 , Supporting Information Tables 2 and 4) . These results are consistent with the induction of the dsDNA damage marker (histone-H2AX(ser139) phosphorylation) by AZA in these cells ( Figure 5 ). On the contrary, DAC treatment caused a general downregulation of genes within these biogroups in A549 cells ( Figure 9 , Supporting Information 
Discussion
In this study, we revealed differential effects of AZA and DAC on cell viability in a panel of NSCLC cell lines, with AZA inducing greater cellular toxicity and markers of apoptosis (PARP cleavage and AnnexinV staining) in comparison to DAC. Furthermore, AZA induced phosphorylation of histone-H2AX(ser139), a marker of dsDNA damage, while DAC had no, or delayed, effect on this endpoint. The striking differences in the response of NSCLC cell lines to these structurally similar cytidine nucleoside analogs further support emerging evidence that the common perception of these agents as mechanistically interchangeable DNA hypomethylating agents should be reconsidered. Figure 6 AZA, but not DAC, strongly induces apoptosis in NsCLC cell lines. A549 and h1299 cells were treated with AZA or DAC (3 µM) for 72 hours, and staining for AnnexinV-FITC (x-axis) and 7-AAD (y-axis) was detected by flow cytometry. A) The percentages of early apoptotic cells and late apoptotic cells are represented in the lower right and upper right quadrants, respectively. representative data of 4 independent experiments are shown. B) Percentage (mean ± sD; n = 4) of apoptotic (early and late) cells with AZA or DAC treatment of A549 cells. *P , 0.001 versus "vehicle". **P = 0.328 versus "vehicle".
# P , 0.001 versus "AZA (3 µM)". C) Percentage (mean ± sD; n = 4) of apoptotic (early and late) cells with AZA or DAC treatment of h1299 cells. *P , 0.001 versus "vehicle". **P = 0.442 versus "vehicle".
# P , 0.001 versus "AZA (3 µM)". Abbreviations: AZA, azacitidine; DAC, decitabine; NsCLC, non-small cell lung cancer. Other recent publications also provide data which differentiate AZA from DAC. For example, an in vitro study evaluating the response of a panel of human cancer cell lines to AZA and DAC showed no correlation in the EC 50 values of the drugs. 24 Another study comparing AZA and DAC activity in the Kasumi-1 AML cell line showed that these drugs had distinct and largely non-overlapping effects on gene expression profiles. 26 We have recently demonstrated that AZA and DAC have different effects on cell viability, protein synthesis, cell cycle, and gene expression in AML cell lines. 25 Similar to the findings in AML cell lines, 25 ,26 we now demonstrate notable differences between AZA and DAC effects on NSCLC cell lines.
Despite the differences in the activities of AZA and DAC on cytotoxicity and induction of dsDNA damage, both AZA and DAC were active in modulating the DNAmediated markers of DNMT1 protein depletion and LINE-1 hypomethylation. While DNA methylation undeniably contributes to cancer development and progression, 27 it is not clear that the anticancer effects of cytidine azanucleoside analogs are solely driven by their DNA hypomethylating activity. Findings from several clinical studies suggest that DNA hypomethylation may not correlate with clinical response. For example, a study found that DNMT depletion caused by DAC treatment did not necessarily result in clinical response. 28 Another clinical trial demonstrated that DAC-induced LINE-1 hypomethylation tended to be greater in patients who did not respond to therapy than in patients who did respond. 29 Stresemann et al showed that a subset of patients who responded to AZA treatment did not display detectable DNA hypomethylation. 30 These results suggest that mechanisms in addition to, or other than, DNA hypomethylation may be critical for the anticancer effects of these drugs.
DAC's potent activity on DNA-mediated markers (DNMT1 depletion and DNA hypomethylation) demonstrates that the lack of cytotoxic activity with DAC was not due to a lack of cellular uptake, drug phosphorylation, and DNA incorporation. It is unclear why DAC does not induce dsDNA damage, despite depleting DNMT1 protein and hypomethylating DNA in the NSCLC cell lines tested. The lack of DAC effects on dsDNA damage and on cytotoxicity is consistent with mounting evidence suggesting that DNA damage may be important for the antitumor effects observed with nucleoside analogs. [31] [32] [33] [34] Published data surrounding DAC-induced DNA damage are mixed. In HeLa and HCT116 cells, DAC induced histone-H2AX(ser139) phosphorylation in a DNMT1-dependent and ataxiatelangiectasia-mutated (ATM)-dependent manner; 34 however, other researchers found that DAC induced DNA single-strand breaks, but not DNA double-strand breaks (DSBs).
35-37 Our results suggest that AZA induces DSBs in NSCLC cell lines, coincident with its induction of apoptosis ( Figure 5 ). DAC did not induce as much DSBs and cell death as AZA in A549 cells. Thus, DSBs may correlate with tumor cell death. Dose and schedule will influence mechanism of action, so the potential for cumulative effects of each drug given at low doses or extended schedules should be tested. Furthermore, potential activities of AZA and DAC on cancer stem cell viability and/or differentiation were not tested here.
In summary, we found that AZA and DAC differentially affected the viability of NSCLC cell lines. While AZA and DAC similarly caused DNMT1 depletion and DNA hypomethylation, the drugs differed in their effects on DNA damage, apoptosis, cell cycle, and gene expression. Perhaps a key difference is that AZA can be incorporated into both RNA and DNA, while DAC is only incorporated into DNA. 25, [38] [39] [40] [41] The functional consequences of AZA incorporation into RNA can include (1) alterations in the synthesis and processing of various species of RNA, (2) inhibition of transcription, and (3) The in vitro anticancer activity of AZA in NSCLC models warrants its evaluation in the clinic. It will be important to consider the multiple mechanisms of AZA activity when selecting therapies for use in combination. 
Materials and methods
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AZA and DAC mechanisms of action in NsCLC was obtained from the National Cancer Institute (NCI) (Bethesda, MD). Cell lines were cultured in their respective media, as recommended by ATCC and NCI. AZA was manufactured at Aptuit (Greenwich, CT) for Celgene Corporation, while DAC was purchased from SigmaAldrich (St Louis, MO). In all experiments, cells were seeded 24 hours before drug treatment and incubated at 37°C and 5% CO 2 . For cell viability assays, H460, H1299, A549, H23, and H1975 cells were seeded in triplicate at 1 × 10 3 , 1 × 10 3 , 1 × 10 3 , 4 × 10 3 , and 4 × 10 3 cells per well, respectively, in 96-well plates using 200 µL of medium per well. As the half-lives of AZA and DAC in cell culture are short (∼8-12 hours) (data not shown), fresh drug was added every 24 hours by replacing medium with drug-containing medium. For all other assays, cells were seeded at 0.6-1.2 × 10 5 cells per well, in 6-well plates, using 4 mL of medium per well, with fresh drug added directly to the medium every 24 hours. At this seeding density, cells are 30%-40% confluent at the start of drug treatments. The concentrations of AZA and DAC used in these experiments are similar to the maximum concentrations (Cmax) achieved in human plasma at clinically used dosages and schedules of administration (3-11 µM AZA and 0.3-1.6 µM DAC).
28,46,47
Cell viability
Cell viability was assessed 72 hours after the initial drug treatment, using the CyQUANT assay (Life Technologies Corporation, Carlsbad, CA). Fluorescence was measured with a spectrophotometer (Molecular Devices, Sunnyvale, CA), and EC 50 values were calculated from three independent experiments using Prism version 5.01 (GraphPad Software, Inc., La Jolla, CA).
Western analysis
For Western analyses of protein levels, cells were washed with phosphate-buffered saline (PBS) and lysed with radio immuno precipitation assay (RIPA) buffer (Cell Signaling Technology, Inc., Danvers, MA) supplemented with 350 mM NaCl and 0.1% sodium dodecyl sulfate (SDS). Cell lysates were sonicated with two 5-second bursts under low amplitude (20%) using the Digital Sonic Dismembrator (ThermoFisher Scientific, Inc., Waltham, MA). Proteins were separated on 4%-12% Bis-Tris NuPAGE gels (Life Technologies Corporation) and transferred to nitrocellulose membranes. DNMT1, phospho-histone-H2AX(ser139), total histone-H2AX, cleaved-PARP, and alpha-tubulin were detected using the Li-Cor Odyssey imaging system (Li-Cor Biotechnology, Lincoln, NE), following incubation with the appropriate primary and secondary antibodies. 
DNA methylation analysis
Genomic DNA was purified from cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA), according to the manufacturer's instructions. DNA yield was quantitated with a NanoDrop 8000 spectrophotometer (ThermoFisher Scientific, Inc.). Genomic DNA (1 µg/sample) was submitted to EpigenDx (Worcester, MA) for bisulfite conversion and pyrosequencing of LINE-1 elements. Briefly, 1 µg of DNA was bisulfite treated using the Zymo DNA Methylation Kit (Zymo Research, Orange, CA) and eluted in 10 µL volume. DNA eluate (1 µL) was used for polymerase chain reaction (PCR) with biotinylated primers to the LINE-1 locus, converting the PCR product to single-stranded DNA GTSE1  CHAF1A  RAD21  SMC3  SSRP1  HMGB2  CCNA2  RECQL  NEIL3  SMC5  TIPIN  MSH5  BRCA2  ASF1A  NBN  CHEK1  DYRK2  AZK  POL1  SFPQ  PMS1  RAD50  HTAT1P  DCLRE1C  MTMR15  CEBPG  FANCE  UVRAGI  MLH3  ATXN3  SMC6  RECQL  FANCF  UPF1  PMS2  GTF2H1  NHEJ1  PPPIR15A  FOXO3A  APTX  POLB  CCNO  TRIAP1  XPC  GADD45A  SFN  PTTG1  LIG1  BCL3  PNKP  MYO6  TP53AP1  DDB2  SESN1  CDKN1A  DDIT3  BTG2 (1) low methylated DNA control, which is human genomic DNA that has been chemically and enzymatically treated to remove the methyl groups; (2) high methylated DNA control, which is human genomic DNA that has been methylated in vitro; and (3) 50/50 mix control, which is an equal mixture of the low methylated DNA and high methylated DNA controls. The percentages of LINE-1 methylation for the low methylated DNA control, the 50/50 mix control, and the high methylated DNA control were 25.8 ± 8.1, 56.2 ± 4.6, and 86.3 ± 6.5, respectively (data not shown).
Flow cytometry
For cell cycle distribution, cells were stained with the NIM-DAPI reagent (Beckman Coulter, Inc., Fullerton, CA). For measurement of early-and late-apoptotic cell populations, cells were stained with AnnexinV-FITC and 7-AAD reagents (Beckman Coulter, Inc.). Samples were processed according to manufacturer's instructions and analyzed on a Cell Lab Quanta MPL flow cytometer (Beckman Coulter, Inc.). The effects of treatment were compared using one-way ANOVA, followed by single step method for adjusting P-values in multiple testing with the bioconductor package multcomp.
gene expression analysis
Cells were lysed using the TRIzol reagent (Life Technologies Corporation), and total RNA was isolated using the miRNeasy kit (Qiagen). Double-stranded cDNA and biotinlabeled cRNA were synthesized using 100 ng of total RNA with Ambion's MessageAmp Premier RNA Amplification Kit (ABI, Foster City, CA). Biotin-labeled cRNA (10 µg) was fragmented and hybridized to each human U133A 2.0 genechip (Affymetrix, Santa Clara, CA). The GC-RMA algorithm was used for normalization, and all analyses were done using GeneSpring 7.3 (Agilent, Santa Clara, CA 
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